Scott T. Tagawa, MD, emphasizes the importance of new data from ASCO 2024 on enfortumab vedotin (EV) for managing advanced urothelial carcinoma, highlighting the importance of dose intensity and patient-reported outcomes.
Dr Tagawa notes that while EV, particularly in combination with pembrolizumab, can cause adverse events such as skin toxicity, neuropathy, and hyperglycemia, dose reductions can improve tolerance without compromising efficacy. He stresses that these insights are crucial for clinicians, especially those new to using these therapies in advanced disease.
